Article:Acute Lymphoblastic Leukemia with Hypereosinophilia in a Child: Case Report and Literature Review (6025476)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q59395190. Its title is Acute Lymphoblastic Leukemia with Hypereosinophilia in a Child: Case Report and Literature Review and the publication date was 2018-06-04. The initial author is Valentina Ferruzzi.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: International Journal of Environmental Research and Public Health

Acute Lymphoblastic Leukemia with Hypereosinophilia in a Child: Case Report and Literature Review

  • Valentina Ferruzzi
  • Elisa Santi
  • Grazia Gurdo
  • Francesco Arcioni
  • Maurizio Caniglia
  • Susanna Esposito

1Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Piazza Menghini 1, 06132 Perugia, Italy; ferruvale@libero.it (V.F.); elisa.santi1988@gmail.com (E.S.)

2Pediatric Oncohematology Unit, Azienda Ospedaliera, Piazza Menghini 1, 06132 Perugia, Italy; grazia.gurdo@ospedale.perugia.it (G.G.); francesco.arcioni@ospedale.perugia.it (F.A.); maurizio.caniglia@alice.it (M.C.)

Publication date (epub): 6/2018

Publication date (ppub): 6/2018

Abstract

Background: Hypereosinophilia in children can be primary or secondary. Numerous malignant diseases can cause hypereosinophilia, but it is seldom caused by acute lymphoblastic leukemia (ALL). In the event of protracted hypereosinophilia, it is extremely important to make a correct differential diagnosis. Case presentation: We present the case of an 11-year-old boy of Moroccan origin with ALL with hypereosinophilic onset (eosinophils in peripheral blood, 10,000/µL) in the absence of other signs of neoplastic disease, and compare this case with 61 similar cases in the literature. Following hospital admission, the patient initially presented with headache-caused nocturnal awakenings, evening fever, and cough, and he also lost approximately 7 kg in weight in a month not associated with sweating or itching. We first performed bone marrow aspiration, which showed an increase in eosinophils without cellular morphological abnormalities, and bone marrow immunophenotyping showed that 4.5% of cells had a phenotype compatible with lymphoid blasts. A lumbar puncture was negative. Given the poor marrow involvement, it was necessary to repeat a new bone marrow aspiration two days later, which showed an increase in blasts to 14%. A concomitant bone marrow biopsy showed an infiltration of blasts typical of B-cell ALL equal to 20–30% with associated hypereosinophilia. Cytogenetic analysis showed an hyperdiploid karyotype: 53–55, XY, +X, add(1)(q21q25), +4, +9, +10, +14, +2, +1, +21/46, XY. Conclusions: ALL is one of the possible causes of persistent hypereosinophilia. In patients with ALL and hypereosinophilia, peripheral hypereosinophilia can precede the appearance of blasts. Due to the negative prognosis and the increased risk of complications in these patients, bone marrow aspiration and biopsy are recommended if common causes of secondary hypereosinophilia are excluded.

Paper

1. Background

Hypereosinophilia (HE) is a relatively common condition. It is diagnosed when the eosinophil count is >500/µL, and depending on the eosinophil count in the peripheral blood, it may be graded as mild (500–1500/µL), moderate (1500–5000/µL), or severe (>5000/µL) [[1],[2]]. Both primary (clonal) and secondary (reactive) forms have been described. Primary HE is usually associated with clonal abnormalities of myeloid lineage, whereas reactive HE accompanies several diseases in which T-cell-dependent cytokine production is the base of HE. Among the conditions that cause secondary HE, there are infections (by different pathogens, including parasites), atopy and allergy, skin and lung diseases, kidney diseases, autoimmune diseases, immunodeficiencies (i.e., Wiskott–Aldrich syndrome, Job syndrome, Nezelof syndrome, graft-versus-host disease, IgA deficiency), systemic mastocytosis, abnormal release of cytokines by immunophenotypically aberrant T lymphocytes, and neoplastic diseases. In less than 1% of the cases, reactive HE is the consequence of acute lymphoblastic leukemia (ALL) [[1],[3]].

Early diagnosis of ALL is essential to assure adequate and effective therapy. Unfortunately, HE frequently precedes common signs and symptoms of ALL by several weeks or months [[4],[5]]. Moreover, in several cases, at onset, disease manifestations are different from those usually detected in ALL and include signs and symptoms caused by eosinophil infiltration of body organs and systems. Diagnosis can be difficult and delayed with high risk for the patient. Here, a case of HE in a child with ALL is reported. Moreover, clinical manifestations of this case are compared to those of the patients aged less than 25 years of age with HE and ALL described and reported in PubMed up until 31 December 2017. This report can provide useful information for understanding the pathophysiological mechanism of ALL associated with HE and for managing HE-related clinical symptoms, favoring a prompt diagnosis of a severe but treatable disease.

2. Case Presentation

An 11-year-old boy of Moroccan origin was admitted to the Pediatric Ward of the Perugia General Hospital in July 2016 because, in the last 15 days, he had suffered from mild fever, chills and night sweats, severe itching, continuous dry cough, and right temporal headache. Moreover, in the month before hospital admission, he had lost approximately 7 kg in weight. Finally, a previous evaluation of blood cell count had revealed HE (eosinophils 10,000/µL) without other significant alterations. The patient denied having recently taken drugs and had had contact with animals. His last trip to his country of origin was in December 2015.

On admission, a blood cell count and a morphological evaluation of a peripheral blood smear confirmed HE (white blood cells 21,950/µL, with eosinophils 13,762/µL, hemoglobin 11.9 g/dL, and platelets 237,000/µL) the absence of other cellular morphological abnormalities. In the following days, the patient presented fatigue and worsening of headache; therefore, attempts to evaluate HE and other signs and symptoms origin were made. A parasitological fecal examination and a Scotch tape test were performed on three samples with negative results. Organ infiltration was excluded through chest X-ray, brain magnetic resonance imaging, echocardiography, and abdominal ultrasound. Toxoplasma, Plasmodium falciparum, Leishmania, Schistosoma, Echinococcus, viral hepatitis, and HIV infection were also excluded. Results of tests regarding comprehensive metabolic panel, inflammatory markers, and autoantibodies were negative excluding autoimmune diseases.

A bone marrow aspiration was performed approximately 20 days after hospital admission. Morphological examination documented an increase in eosinophils without cellular morphological abnormalities, and bone marrow immunophenotyping showed that 4.5% of the cells had a phenotype compatible with lymphoid blasts. A lumbar puncture was negative. However, given the poor marrow involvement, it was necessary to repeat the bone marrow aspiration two days later; the results of the new aspiration showed an increase in blasts to 14% (Figure 1) with a normal immunophenotype on mature B ant T cells. Concomitant bone marrow biopsy showed a cellularity of 40% with an infiltration of blasts typical of B-cell ALL equal to 20–30% with marked associated hypereosinophilia.

Cytogenetic analysis showed a hyperdiploid karyotype: 53–55, XY, +X, add(1)(q21q25), +4, +9, +10, +14, +2, +1, +21/46, XY; FISH analysis confirmed the numeric and structural abnormalities revealed by karyotype, without cryptic additional events. In particular, no abnormalities were found on chromosome 5. The main molecular leukemic rearrangements—including BCR/ABL, MLL/AF4, TEL/AML1, and E2A/PBX1—were negative. The in vitro production of interleukin (IL)-5 by T CD4 + lymphocytes was increased (41%) compared to the negative control (11%).

A few days after the start of prednisone prophase, a marked drop in peripheral eosinophil count and rapid clinical improvement were evident. On day 78, the patient was assigned to the standard risk group of the AIEOP ALL 2009 protocol. The patient is now undergoing maintenance therapy (6 Mercaptopurin plus Methotrexate) and will stop it on August 2018. Until now, the patient remains in complete remission; no further increase of eosinophil count was demonstrated.

3. Discussion

According to the algorithm suggested by the revised 2016 World Health Organization (WHO) Classification of Eosinophilic Disorders, the first step that should be made to classify a HE case is the screening of secondary cases [[1]]. Medical history, clinical signs and symptoms, and laboratory and imaging tests can significantly contribute to the identification of the condition that causes HE and favor risk stratification and management. When reactive causes of HE are excluded, the following step is the evaluation of primary bone marrow disorders. Blood smear, blood tests, and bone marrow morphologic, cytogenetic, and immunophenotypic evaluation can lead to the diagnosis of one of the myeloid neoplasms recently classified by WHO on the base of clinical manifestations and genetic characteristics (acute myeloid leukemia and related neoplasms, myeloproliferative neoplasms, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, mastocytosis, and myeloid/lymphoid neoplasms) [[1]]. Moreover, in a lower number of cases, a lymphoid variant of HE (T-cell lymphomas, Hodgkin lymphoma, and ALL) can be diagnosed. Evidence of ALL makes the screening of the peripheral blood superfluous for genetic alterations such as FIP1L1-PDGFRA gene fusion, reciprocal translocations involving 4q12 (PDGFRA), 5q31-q33 (PDGFRB), 8p11–12 (FGFR1), or 9p24 (JAK2) that are recommended by WHO [[1]] and are useful to decide risk and risk-adapted therapy for myeloid neoplasms. On the contrary, it should be mandatory to perform cytogenetic analysis of lymphocytes in order to evaluate the most common abnormalities that can explain HE pathogenesis and characterize severity and response to therapy of ALL.

The mechanism of HE that accompanies some neoplastic diseases has not yet been fully clarified. It has been suggested that antigens expressed by tumor cells or exogenous factors such as viral infections can lead to T-cell stimulation and increased production of eosinophilopoietic growth factors [[1]]. However, regarding the development of HE in patients with ALL it seems likely that it is the consequence of a mixture of clonal and reactive processes [[6]]. Clonal origin of HE can be excluded as precursors of eosinophils in the bone marrow of these individuals have no genetic abnormalities suggesting that these cells have different hematopoietic origin. However, abnormal T-cell lymphocytes can be detected in lymphoid variant of HE syndromes. Absence of CD3 (e.g., CD3−CD4+), presence of immature T-cell (e.g., CD3+CD4−CD8−−), elevated CD5 expression on CD3-CD4+ cells, and loss of surface CD7 and/or expression of CD27 have been repeatedly described in these patients [[7]]. It has been supposed that these abnormal lymphocytes can produce significant amounts of Th2 cytokines (IL-3, IL-4, IL-5, IL-13) capable of inducing eosinophil proliferation and survival. This hypothesis is strongly supported by the evidence that in many of patients with HE and ALL, a relevant increase in blood concentration of one or more of these cytokines can be demonstrated. Further evidence of the strict relationship between HE and Th2 cytokine production is given by the few patients with ALL-associated HE in whom genetic abnormalities, such as t (5; 14) (q31; q32) and del (5) (q15q33), induce IL-3 gene activation and relevant production of this eosinophilopoietic cytokine [[8],[9],[10]].

Cases of HE secondary to ALL are very rare. In addition to this child, only 61 patients <25 years (mean age 11 years) with HE and ALL have been described since 1973 to December 2017 (Table 1) [[8],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21],[22],[23],[24],[25],[26],[27],[28],[29],[30],[31],[32],[33],[34],[35],[36],[37],[38],[39],[40],[41],[42],[43],[44],[45],[46],[47],[48],[49],[50],[51],[52],[53],[54],[55],[56],[57],[58]].

Most of them had clinical and laboratory characteristics that can be found in the described patient and can be considered typical of this kind of disease. Generally, ALL with HE is a B-cell disease that occurs mainly in males. Frequently, HE is diagnosed before the onset of classic signs and symptoms of ALL and disappears after therapy during remission of the disease. Moreover, in many patients, no blast is detected in the peripheral smear when HE is diagnosed. Finally, several clinical manifestations not found in typical ALL cases accompany HE. They are mainly due to eosinophil infiltration of different body organs and systems and can significantly condition final prognosis of ALL independently of the blast level at onset [[33]]. In this case, in addition to non-specific symptoms, such as fever and fatigue, respiratory symptoms were clinically important, as in 43% of reported patients. In other cases, HE was associated with skin erythema (33%; often with a vasculitis component) and cardiovascular alterations (13%). Particularly, the cardiac infiltration of eosinophils can cause a progression towards restrictive cardiomyopathy, leading to Loeffler endocarditis and death [[22],[33],[59]]. Moreover, an increased risk of thromboembolic events was found, sometimes as early as the onset of the disease, and this must be completely taken into account by clinicians because therapy of ALL involves protocols that include prothrombotic drugs such as L-asparaginase [[7],[60],[61]]. In this case, increase in IL-5 blood concentration was found, confirming the reactive origin of HE. No genetic abnormality of lymphocytes was found.

4. Conclusions

As our case and review of the literature showed, ALL is one of the possible causes of persistent hypereosinophilia. In patients with ALL and hypereosinophilia, peripheral hypereosinophilia can precede the appearance of blasts. Due to the negative prognosis and the increased risk of complications in these patients, bone marrow aspiration and biopsy are recommended if common causes of secondary hypereosinophilia are excluded.

Acknowledgements

Acknowledgments

The authors thank the staff of Falini’s laboratory for the support in the diagnostics as well as the patient and his parents for allowing us to publish this case report.

References

  1. J. GotlibWorld Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and managementAm. J. Hematol.2015921243125910.1002/ajh.2488029044676
  2. A. AmshalomA. LevL. TrakhtenbrotH. GolanB. WeissN. AmariglioG. RechaviR. SomechSevere eosinophilia in children: A diagnostic dilemmaJ. Pediatr. Hematol. Oncol.20133530330610.1097/MPH.0b013e318290bf0b23612381
  3. R. BachhuberJ.H. FitchenB. Harty-GolderRash and eosinophilia in a 23-year-old manWest. J. Med.19821372212276959420
  4. G. SpitzerO.M. GarsonLymphoblastic leukemia with marked eosinophilia: A report of two casesBlood1973423773844516523
  5. R. ParasoleF. PetruzzielloA. De MatteoG. MaistoL. CastelliM.E. ErricoG. MennaV. PoggiHypereosoinophilia in childhood acute lymphoblastic leukemia at diagnosis: Report of 2 cases and review of the literatureItal. J. Pediatr.2014403610.1186/1824-7288-40-3624717004
  6. J.E. KahnM. GrohG. Lefèvre(A Critical Appraisal of) Classification of Hypereosinophilic DisordersFront. Med.2017421610.3389/fmed.2017.0021629259972
  7. F. RoufosseHypereosinophilic syndrome variants: Diagnostic and therapeutic considerationsHaematologica2009941188119310.3324/haematol.2009.01042119734412
  8. T.F. HoganW. KossA.J. MurgoR.S. AmatoJ.A. FontanaF.L. VanScoyAcute lymphoblastic leukemia with chromosomal 5;14 translocation and hypereosinophilia: Case report and literature reviewJ. Clin. Oncol.1987538239010.1200/JCO.1987.5.3.3823546615
  9. J.C. GrimaldiT.C. MeekerThe t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain geneBlood198973208120852499362
  10. T.C. MeekerD. HardyC. WillmanT. HoganJ. AbramsActivation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophiliaBlood1990762852892114933
  11. A.M. AliA. RashidiJ.F. DiPersioAcute lymphoblastic leukemia presenting with hypereosinophilia: Case report and review of the literatureBlood Cells Mol. Dis.2017659710010.1016/j.bcmd.2016.08.00427634176
  12. S. BomkenS. HaighN. BownP. CareyK. WoodK. WindebankCutaneous B-lymphoblastic lymphoma with IL3/IgH translocation presenting with hypereosinophilia and acute endocarditisPediatr. Blood Cancer2015621055105710.1002/pbc.2531825382309
  13. K.K. SahuP. MalhotraA. KhadwalM.S. SachdevaP. SharmaN. VarmaS.C. VarmaHypereosinophilia in Acute Lymphoblastic Leukemia: Two Cases with Review of LiteratureIndian J. Hematol. Blood Transfus.20153146046510.1007/s12288-014-0436-726306071
  14. A. HolmesJ. CovielloG. VelagaletiAcute multilineage (B/myeloid) leukemia with RUNX1 duplication/amplification and hypereosinophiliaEur. J. Haematol.20149344945210.1111/ejh.1233324912843
  15. A. RezamandZ. GhorashiS. GhorashiN. NezamiEosinophilic presentation of acute lymphoblastic leukemiaAm. J. Case Rep.20131414314623869247
  16. A.C. AyhanC. TimurY. AyhanB. CakirM. ErguvenDoes Hypereosinophilic Syndrome Precede Common B Acute Lymphoblastic Leukemia in Childhood? A Case ReportActa Haematol.20121279010.1159/00033308522156491
  17. D. KobayashiK. KogawaK. ImaiT. TanakaA. SadaS. NonoyamaHyper-eosinophilia in granular acute B-cell lymphoblastic leukemia with myeloid antigen expressionPediatr. Int.20125454354610.1111/j.1442-200X.2011.03471.x22830543
  18. Y. GuoX.J. ChenS.C. WangChildhood acute lymphoblastic leukemia with hypereosinophilia: Two cases and literature reviewZhonghua Xue Ye Xue Za Zhi20123313113222730666
  19. S. GeorgeP. KumarG. QuartaA. ShankarR. HoughS. SamarasingheLoeffler myocarditis in pre-B acute lymphoblastic leukemia with t(5;14)(q31;q32)Br. J. Haematol.201215751710.1111/j.1365-2141.2012.09098.x22436047
  20. C.H. ChenI.C. TsaiS.L. JanW.L. TsaiC.C. ChenMDCT evaluation of cardiac involvement in hypereosinophilic syndromeTex. Heart Inst. J.20113816616921494529
  21. M.H. NesheliT.G. MoghaddamY. ZahedpashaA.R. NorouziAcute Lymphoblastic Leukemia with Eosinophilia and Strongyloides stercoralis HyperinfectionIran. J. Pediatr.20112154955223056848
  22. Y.L. NieS.L. JanL.S. FuT.K. ChangJ.D. WangCongestive heart failure as presentation of acute lymphoblastic leukemia with eosinophiliaBr. J. Haematol.201014963310.1111/j.1365-2141.2010.08103.x20148889
  23. M.D. FilesJ.A. ZenelL.B. ArmsbyS.M. LangleyA child with eosinophilia, Loffler endocarditis, and acute lymphoblastic leukemiaPediatr. Cardiol.20093053053210.1007/s00246-008-9360-719123015
  24. R. SuttonM. LonerganH. TappN.C. VennM. HaberM.D. NorrisT.A. O’BrienF. AlvaroT. ReveszTwo cases of hypereosinophilia and high-risk acute lymphoblastic leukemiaLeukemia2008221463146510.1038/sj.leu.240509618200036
  25. S.A. RezkL. WheelockJ.A. FletcherA.M. OliveiraC.P. KeukerP.E. NewbergerB. XuB.A. WodaP.M. MironAcute lymphoblastic leukemia with eosinophilia and unusual karyotypeLeuk. Lymphoma2006471176117910.1080/1042819050050871016840218
  26. M.C. RapanottiR. CarusoS. BernardiniV. ColettiF. Lo-CocoG. De RossiIdiopathic hypereosinophilic syndrome: A case evolving in B-lymphoblastic lymphomaLeuk. Res.20052997597910.1016/j.leukres.2005.01.01015978951
  27. H. HorigomeR. SumazakiN. IwasakiN. ImotoH. KinugasaM. SaitoA. MatsuiFatal eosinophilic heart disease in a child with neurofibromatosis-1 complicated by acute lymphoblastic leukemiaHeart Vessels20052012012210.1007/s00380-004-0786-415912309
  28. F. WilsonA. TefferiAcute lymphocytic leukemia with eosinophilia: Two case reports and a literature reviewLeuk. Lymphoma2005461045105010.1080/1042819050008553716019556
  29. F. GirodonE. BergoinB. FavreS.A. MarthaF. MugneretG. CouillautP.M. CarliM. MaynadiéHypereosinophilia in acute B-lineage lymphoblastic leukemiaBr. J. Haematol.200512956810.1111/j.1365-2141.2005.05469.x15916678
  30. L.S. Lamb Jr.R. NeubergJ. WelshR. BestM. Stetler-StevensonA. SorrellT-Cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemiaCytom. Part B Clin. Cytom.200565374110.1002/cyto.b.2003315786509
  31. A.J. ChienZ.B. ArgenyR.M. ColvenP. KirbyAcute lymphoblastic leukemia presenting with urticarial plaques and hypereosinophilia in a childJ. Am. Acad. Dermatol.200451S151S15510.1016/j.jaad.2004.04.01815577757
  32. C.A. NuñezT.F. ZipfW.M. RobertsL.J. MedeirosK. HayesC.E. Bueso-RamosMolecular monitoring of cerebrospinal fluid can predict clinical relapse in acute lymphoblastic leukemia with eosinophiliaArch. Pathol. Lab. Med.200312760160512708906
  33. T.T. WynnN.A. HeeremaS. HammondM. RanalliS.B. KahwashAcute lymphoblastic leukemia with hypereosinophilia: Report of a case with 5q deletion and review of the literaturePediatr. Dev. Pathol.2003655856310.1007/s10024-003-2019-815018456
  34. A. HillD. MetryUrticarial lesions in a child with acute lymphoblastic leukemia and eosinophiliaPediatr. Dermatol.20032050250510.1111/j.1525-1470.2003.20610.x14651570
  35. T.P. DonahueImages in cardiology: Loeffler’s Endocarditis Resulting from Acute Lymphoblastic LeukemiaClin. Cardiol.20022534510.1002/clc.495025070812109869
  36. L.L. BjerregaardS. RosthoøjVertebral compression and eosinophilia in a child with acute lymphatic leukemiaJ. Pediatr. Hematol. Oncol.20022431331510.1097/00043426-200205000-0001911972103
  37. C. BernasconiHypereosinophilia in acute lymphoblastic leukemia: An association to be rememberedHaematologica20018689311524261
  38. P. JainR. KumarS. GujralA. KumarA. SinghY. JainS. DubeyM. AnandL.S. AryaGranular acute lymphoblastic leukemia with hypereosinophilic syndromeAnn. Hematol.20007927227410.1007/s00277005059210870483
  39. G. NarayananB.M. HussainB. ChandralekhaC. SivasankarM.K. NairHyperosinophilia syndrome in acute lymphoblastic leukemia, case report and leterature reviewActa Oncol.20003924124310859020
  40. R. KitaH. EnokiharaS. NagashimaS. TsunogakeH. YamatoK. SaitoS. FurusawaH. ShishidoY. FukushimaT. FukudaGM-CSF and eosinophil chemotactic factors in an acute lymphoblastic leukemia patient with eosinophiliaActa Haematol.19939014414710.1159/0002043968291374
  41. J. BlattR. ProujanskyM. HornC. PhebusD. LongworthL. PenchanskyIdiopathic hypereosinophilic syndrome terminating in acute lymphoblastic leukemiaPediatr. Hematol. Oncol.1992915115510.3109/088800192090183301388044
  42. E. Rios-HerranzR. Fores-CachonJ.L. Diez-MartinM.N. FernandezHypereosinophilia and acute lymphoblastic leukemiaPostgrad. Med. J.19916770270310.1136/pgmj.67.789.702-a1924073
  43. P. DervanianC. AcarV.A. JebaraA. DelocheJ.N. FabianiA. CarpentierMitral valvuloplasty for endomyocardial fibrosis in a child with acute leukemia and hypereosinophiliaArch. Mal. Coeur Vaiss.199184186118641793325
  44. E. BaumgartenR.D. WegnerR. FenglerW.D. LudwigU. Schulte-OverbergC. DomeyerJ. SchüürmannG. HenzeCalla-positive acute leukemia with t(5q;14q) translocation and hypereosinophilia—A unique entity?Acta Hematol.198982859010.1159/0002052892508400
  45. T.S. McConnellK. FoucarW.R. HardyJ. SaikiThree-way reciprocal chromosomal traslocation in an acute lymphoblastic leukemia patient with hypereosinophilia syndromeJ. Clin. Oncol.198752042204410.1200/JCO.1987.5.12.20423479532
  46. P. KeeneB. MendelowM.R. PintoW. BezwodaL. MacDougallG. FalksonP. RuffR. BernsteinAbnormalities of chromosome 12p13 and malignant proliferation of eosinophils: A nonrandom associationBr. J. Haematol.198767253110.1111/j.1365-2141.1987.tb02291.x3478077
  47. A.M. TanP.J. DownieH. EkertHypereosinophilia syndrome with pneumonia in acute lymphoblastic leukemiaAust. Pediatr. J.198723359361
  48. M.L. TroxellG.M. MillsR.C. AllenThe hypereosinophilic syndrome in acute lymphocytic leukemiaCancer1984541058106110.1002/1097-0142(19840915)54:6<1058::AID-CNCR2820540621>3.0.CO;2-06590112
  49. P.S. GaynonF. Gonzalez-CrussiExaggerated eosinophilia and acute lymphoid leukemiaAm. J. Pediatr. Hematol. Oncol.1984633433710.1097/00043426-198423000-000196595948
  50. R.R. ChilcoteE. PergamentR. KretschmerJ.C. MikutaThe hypereosinophilic syndrome and lymphoblastic leukemia with extra C-group chromosome and q14+ markerJ. Pediatr.1982101576010.1016/S0022-3476(82)80180-76953225
  51. E. BottoneP. MacchiaR. ConsoliniAcute lymphoblastic leukemia first appearing as hypereosinophiliaEur. J. Pediatr.1982132858810.1007/BF00442339
  52. D. CatovskyC. BernasconiP.J. VerdonckA. PostmaJ. HowsA. van der Does-van den BergJ.K. ReesG. CastelliE. MorraD.A. GaltonThe association of eosinophilia with lymphoblastic leukemia or lymphoma: A study of seven patientsBr. J. Haematol.19804552354310.1111/j.1365-2141.1980.tb07174.x6932954
  53. R.S. WimmerR.B. RaneyJ.L. NaimanHypereosinophilia with acute lymphocytic and acute myelocytic leukemia in childhoodJ. Pediatr.19789224424610.1016/S0022-3476(78)80018-3271709
  54. D. GeltnerG. FriedmanE. NaparstekH. GranotA. PolliackAcute lymphoblastic leukemia its occurrence with hypereosinophilic syndrome and bilateral spontaneous pneumothoraxArch. Intern. Med.197813829229310.1001/archinte.1978.03630260082021272863
  55. F. PereiraH. MorenoW. CristR. ErmocillaLoffler’s endomyocardial fibrosis, eosinophilia, and acute lymphoblastic leukemiaPediatrics197759950951266693
  56. R.P. NelkenJ.A. Stockman, 3rd. The hypereosinophilic syndrome in association with acute lymphoblastic leukemiaJ. Pediatr.19768977177310.1016/S0022-3476(76)80801-31068266
  57. S.C. RizzoG. FontanaG. MariniC.L. BalduiniMarked eosinophilia associated with acute lymphoblastic leukemiaHaematologica1976618185820600
  58. P.M. BlattG. RothsteinH.L. MillerW.J. CatheyLoffler’s andomyocardial fibrosis with eosinophilia in association with acute lymphoblastic leukemiaBlood1974444894934547249
  59. P.F. WellerG.J. BubleyThe idiopathic hypereosinophilic syndromeBlood199483275927798180373
  60. W.R. HardyR.E. AndresonThe hyperosinophilic syndromesAnn. Intern. Med.1968681220122910.7326/0003-4819-68-6-12205653621
  61. A. UtsunomiyaT. IshidaA. InagakiT. IshiiH. YanoH. KomatsuS. IidaK. YonekuraS. TakeuchiY. TakatsukaClinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: A blood eosinophilia is a significant unfavorable prognostic factorLeuk. Res.20073191592010.1016/j.leukres.2006.10.01717123603
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6025476/fullTextXML. The license for the article is Creative Commons Attribution. The main subject has been identified as precursor lymphoblastic lymphoma/leukemia.